Terms: = Skin cancer AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978 AND Treatment
7 results:
1. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].
Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
3. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
4. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
5. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
Pemmaraju N; Carter BZ; Bose P; Jain N; Kadia TM; Garcia-Manero G; Bueso-Ramos CE; DiNardo CD; Bledsoe S; Daver NG; Popat U; Konopleva MY; Zhou L; Pierce S; Estrov ZE; Borthakur GM; Ohanian M; Qiao W; Masarova L; Wang X; Mak PY; Cortes J; Jabbour E; Verstovsek S
Blood Adv; 2021 Aug; 5(16):3163-3173. PubMed ID: 34424319
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
[TBL] [Abstract] [Full Text] [Related]
7. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
[TBL] [Abstract] [Full Text] [Related]
